Patents by Inventor Sebastien Andre Campos
Sebastien Andre Campos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230219986Abstract: The present invention provides a novel aminopyrimidine compound as a fourth-generation EGFR (T790M/C797S mutation) selective inhibitor, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating a cell proliferative disease, such as a cancer, by using the compound of the present invention.Type: ApplicationFiled: March 19, 2021Publication date: July 13, 2023Applicants: QILU PHARMACEUTICAL CO., LTD., QILU PHARMACEUTICAL CO., LTD.Inventors: Wei DENG, Shansong ZHENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
-
Publication number: 20230192734Abstract: Provided are a class of compounds, represented by formula (I??), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds of the present invention to treat cell proliferative diseases, such as cancers.Type: ApplicationFiled: April 13, 2021Publication date: June 22, 2023Inventors: Shansong ZHENG, Wei DENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
-
Patent number: 10793559Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: September 17, 2019Date of Patent: October 6, 2020Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
-
Patent number: 10730862Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: GrantFiled: January 11, 2013Date of Patent: August 4, 2020Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of CambridgeInventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
-
Publication number: 20200071311Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: September 17, 2019Publication date: March 5, 2020Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
-
Patent number: 10457674Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: GrantFiled: February 10, 2017Date of Patent: October 29, 2019Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
-
Publication number: 20190161480Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: August 7, 2017Publication date: May 30, 2019Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Sebastien Andre CAMPOS, Samuel Edward DALTON, Vipulkumar Kantibhai PATEL
-
Publication number: 20190127359Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: ApplicationFiled: December 18, 2018Publication date: May 2, 2019Inventors: CRAIG M. CREWS, DENNIS BUCKLEY, ALESSIO CIULLI, WILLIAM L. JORGENSEN, PETER C. GAREISS, INGE VAN MOLLE, JEFFREY GUSTAFSON, HYUN-SEOP TAE, JULIEN MICHEL, DENTON WADE HOYER, ANKE G. ROTH, JOHN DAVID HARLING, IAN EDWARD DAVID SMITH, AFJAL HUSSAIN MIAH, SEBASTIEN ANDRE CAMPOS, JOELLE LE
-
Publication number: 20190040051Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.Type: ApplicationFiled: February 10, 2017Publication date: February 7, 2019Inventors: Niall Andrew ANDERSON, Nicholas Paul BARTON, Sebastien Andre CAMPOS, Edward Paul CANNONS, Anthony William James COOPER, Kenneth David DOWN, Kevin James DOYLE, Julie Nicole HAMBLIN, Graham George Adam INGLIS, Armelle LE GALL, Vipulkumar Kantibhai PATEL, Simon PEACE, Andrew SHARPE, Gemma Victoria WHITE
-
Patent number: 9993514Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.Type: GrantFiled: July 1, 2014Date of Patent: June 12, 2018Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Sebastien Andre Campos, John David Harling
-
Patent number: 9988376Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.Type: GrantFiled: July 1, 2014Date of Patent: June 5, 2018Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Sebastien Andre Campos, John David Harling, Afjal Hussain Miah, Ian Edward David Smith
-
Publication number: 20160368911Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation.Type: ApplicationFiled: July 1, 2014Publication date: December 22, 2016Applicant: Glaxosmithkline Intellectual Property Development LimitedInventors: Sebastien Andre CAMPOS, John David HARLING, Afjal Hussain MIAH, Ian Edward, David SMITH
-
Publication number: 20160136230Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.Type: ApplicationFiled: July 1, 2014Publication date: May 19, 2016Inventors: Sebastien Andre CAMPOS, John David HARLING
-
Publication number: 20140356322Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: ApplicationFiled: January 11, 2013Publication date: December 4, 2014Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Dentin Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
-
Patent number: 8575181Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.Type: GrantFiled: August 7, 2009Date of Patent: November 5, 2013Assignee: GlaxoSmithKline LLCInventors: Sebastien Andre Campos, Diane Mary Coe, Naimisha Trivedi
-
Publication number: 20110135670Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.Type: ApplicationFiled: August 7, 2009Publication date: June 9, 2011Applicant: GLAXOSMITHKLINE LLCInventors: Sebastien Andre Campos, Diane Mary Coe, Naimisha Trivedi
-
Publication number: 20100179139Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.Type: ApplicationFiled: May 29, 2008Publication date: July 15, 2010Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Patent number: 7687532Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.Type: GrantFiled: January 27, 2005Date of Patent: March 30, 2010Assignee: GlaxoSmithkline LLCInventors: Sebastien Andre Campos, Stephen Swanson, Ann Louise Walker
-
Publication number: 20100035917Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.Type: ApplicationFiled: September 20, 2007Publication date: February 11, 2010Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
-
Publication number: 20090023725Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.Type: ApplicationFiled: January 27, 2005Publication date: January 22, 2009Inventors: Paul Bamborough, Sebastien Andre Campos, Vipulkumar Kantibhai Patel, Stephen Swanson, Ann Louise Walker